513 related articles for article (PubMed ID: 17996587)
1. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
2. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
[TBL] [Abstract][Full Text] [Related]
3. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
4. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
Giuliani N; Rizzoli V; Roodman GD
Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies for bone disease.
Roodman GD
Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
[TBL] [Abstract][Full Text] [Related]
9. Bone markers in multiple myeloma.
Heider U; Fleissner C; Zavrski I; Kaiser M; Hecht M; Jakob C; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1544-53. PubMed ID: 16765040
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
11. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
12. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.
Bataille R; Chappard D; Marcelli C; Dessauw P; Baldet P; Sany J; Alexandre C
J Clin Invest; 1991 Jul; 88(1):62-6. PubMed ID: 2056131
[TBL] [Abstract][Full Text] [Related]
13. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.
Giuliani N; Rizzoli V
Leuk Lymphoma; 2007 Dec; 48(12):2323-9. PubMed ID: 18067006
[TBL] [Abstract][Full Text] [Related]
14. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
15. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
16. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.
Pearse RN
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6274s-6278s. PubMed ID: 17062713
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
18. Osteoclast-osteoblast communication.
Matsuo K; Irie N
Arch Biochem Biophys; 2008 May; 473(2):201-9. PubMed ID: 18406338
[TBL] [Abstract][Full Text] [Related]
19. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Mitsiades CS; McMillin DW; Klippel S; Hideshima T; Chauhan D; Richardson PG; Munshi NC; Anderson KC
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1007-34, vii-viii. PubMed ID: 17996586
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of myeloma bone disease.
Roodman GD
Leukemia; 2009 Mar; 23(3):435-41. PubMed ID: 19039321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
